Skip to main content
Premium Trial:

Request an Annual Quote

White Papers and Videos

Colli-Pee - Performance of A Game-Changing Sampling Device for HPV-Based Cervical Cancer Screening

White Paper

Cervical cancer causes over 300,000 deaths per year. The introduction of screening programs to detect pre-cancer lesions has resulted in a 50 percent reduction of premature deaths. However, non-attendance rates are high: on average 40 percent of women living in developed countries and 80 percent in developing countries do not participate in screening due to the invasiveness of cervical sampling, cultural reasons, lack of time, and the need to visit a clinician.

This whitepaper from Novosanis explains the performance of Colli-Pee — a self-sampling urine-capturing device that collects the first 20 ml of urine flow — in HPV-based cervical cancer screening, highlighting current studies and literature in the field and demonstrating the device’s use for non-invasive, self-administered screening.

Trends in Variant Interpretation Workflows: Expert Insights to Advance NGS Oncology Profiling


Please join GenomeWeb and Qiagen for an on-demand roundtable discussion where a panel of experts reviews challenges and opportunities around genomic variant interpretation workflows in the field of oncology.

Recently, GenomeWeb and Qiagen partnered on a survey that allowed participants to assess their oncology variant interpretation workflows. This webinar presents the results of the survey and offers an interactive environment for clinical labs to assess their own variant interpretation capabilities.

The discussion covers a range of capabilities related to variant interpretation workflows, including:

  • Resources and skills
  • Workflow optimization
  • Variant interpretation content knowledge.

Demo White Paper - Test ONLY

White Paper

Lorem ipsum dolor sit amet, consectetur adipiscing elit. In sollicitudin lacus in dolor posuere, hendrerit maximus sem eleifend. Proin sed sollicitudin justo. Curabitur quam nulla, ornare a massa sed, dictum venenatis neque. In elit nunc, cursus et aliquam a, mollis ac ante. Ut et arcu magna. Nunc aliquam malesuada ligula sed convallis. Cras consequat arcu ut ex tristique tincidunt. Nulla at tristique sem. Ut ut tempus libero, eget sodales nibh. Quisque odio metus, cursus sed velit nec, porta facilisis mauris. Nunc dapibus diam mollis tristique condimentum.

Lessons on Sample Accessioning and Processing at Clinical Labs During a Pandemic

White Paper

When the COVID-19 pandemic escalated in March 2020, many diagnostic labs pivoted to focus on detecting SARS-CoV-2, while others sprang up de novo to meet the massive and urgent demand. Each was faced with the challenge of adapting sample accessioning and processing workflows to keep pace with the unprecedented demand for testing, without sacrificing accuracy.

This e-book details the major challenges labs have faced and how they have adapted to handle the sustained demand for large-scale sample accessioning and testing. Nischay Mishra, PhD, an Assistant Professor of Epidemiology and infectious disease diagnostic developer at the Center for Infection and Immunity at the Columbia University Medical Center, provides insight and key takeaways on next steps to improve testing workflows.

Case Study: Eppendorf OEM for a Clinical Analyzer

White Paper

This case study describes an Eppendorf OEM project that provided exceptional quality customized consumables for a clinical analyzer, consisting of both tips and sample vessels. The solution required an ultra-high throughput production cleanroom environment, assuring batch-to-batch consistency, and supply continuity to the partner, a large diagnostics provider.

Positioning Your Diagnostics Lab for Success

White Paper

Clinical and molecular diagnostics labs have unique needs. A purpose-built LIMS meets those needs head on, with request management capabilities, next-gen sequencing workflows, consumables management, and statistical process control. LabVantage Diagnostics, a preconfigured lab information management system, handles these responsibilities and more as a single, centralized platform.

This white paper describes the benefits of deploying an industry-specific LIMS and how that positions your diagnostics lab for success. This includes faster turnaround times, lowering the cost of testing, consistent specimen management, clear and compliant e-signatures, compliance with CLIA, CAP and other regulations, data integrity, and more. Find out how years of LIMS customization for diagnostics labs has become an off-the-shelf solution to optimize your operations.

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?


This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.

The application of plasma samples bearing circulating tumor DNA (ctDNA) as a surrogate for solid tumor biopsy is an area of significant research and clinical interest. Genomic aberrations associated with ctDNA have been demonstrated to mirror the solid tumor mutational landscape and have the potential for early diagnosis of cancer as well as monitoring and tracking biomarkers associated with residual disease and/or recurrence.

Despite this promise, there are still open questions regarding the best way to implement liquid biopsy approaches in the clinical setting. Our panel brings together academic, clinical, and industry experts in liquid biopsy technologies who will describe the applications of this technique and discuss its benefits and shortcomings in the context of cancer disease management.

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion


Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. With a growing number of available assays and more labs offering testing, it is essential to have consistency in reporting and the ability to compare results and validate current or new methods.

This on-demand webinar features a panel of experts who provide key insights into the current needs in prenatal testing, the complexities of selecting an assay format and performing quality control, as well as other challenges that labs face when setting up and validating an NIPT assay.

The panelists bring a wealth of expertise and differing viewpoints in clinical laboratory practice, diagnosis of pregnancy complications, and new molecular methods for diagnosis and treatment of pregnancy anomalies and complications. 

A Real-Time-Assay for the fast and gel-free detection of Rhesus Weak D Type 1/1.1 to Type 3

White Paper

In emergency situations, molecular typing of the Rhesus blood group can be helpful but is considered a complicated and slow procedure. This poster shares details from a study that demonstrates reliable and quick real-time PCR typing for weak D types 1, 2 and 3 for a wide range of DNA concentrations.

Fast Real-Time PCR Detection of HLA-B*27 Directly from Blood Using a Specialized Stabilizing Reagent

White Paper

Whole blood or buffy coat is the most commonly used sample material in diagnostic procedures, but often negatively effects PCR applications. In this study we show the tremendous stabilizing effect of a reagent called Blood Booster on direct real-time amplification from fresh blood samples in the FastQ B*27 kit.

The Human Gene Mutation Database: Empowering a Generation of Geneticists for Precision Medicine


The Human Gene Mutation Database (HGMD) is a manually curated, comprehensive collection of disease-causing, germline mutations. Since 1996, a team of experts has manually catalogued over a quarter of a million mutations for the database.  

This talk will feature a retrospective view of HGMD, how it has grown over time, and the research that it has enabled. In particular, our speakers will talk about how HGMD has helped move precision medicine forward by providing translational research and diagnostic applications with the most comprehensive survey of literature on genetic mutations responsible for human inherited diseases, supporting standardized interpretation for germline diseases. 

2 Tools for Overcoming Your Clinical Lab’s Toughest Quality Control Challenges

White Paper

Whatever practices you use for NGS assay development, validation, and performance monitoring, your goal is the same: Your results must be as accurate, precise, and consistent as possible.

That goal is within reach. And in this paper, we’ll show you how. By reading this white paper, you will learn:

· Why quality control is so challenging for NGS labs

· How reference materials may be the key to quality control

· The 9 key characteristics of sufficient NGS reference materials

· How to use QC metrics to monitor the health of your NGS assays

· 7 QC data management must-haves